Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx in 2009: Re-Politicizing Drug Prices

This article was originally published in RPM Report

Executive Summary

Remember when the Democrats took over Congress and promised to do something about prescription drug prices under Part D? They didn't get very far, and they haven't been talking about it since. But when beneficiaries get ready to renew their Part D coverage in 2009-and see how much their costs are going up-there may be a lot more to talk about.

You may also be interested in...



Health Care Reform and the Biopharma Sector: A Complete Tactical Victory

The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?

Health Care Reform and the Biopharma Sector: A Complete Tactical Victory

The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?

Not So Random Selection: Medicare Agency Cuts "Churn" In Part D Enrollment

One of the Obama Administration's first moves in managing the Medicare Part D benefit is to tamp down on the number of beneficiaries who will be randomly assigned to a new plan on Jan. 1. Stability is good for the program politically, but it may also be a sign of more hands-on management by the Medicare agency in the years ahead.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel